Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.37 |
| ▸ | GCG | P01275 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11901185 | 0.81 | GCG (0.36) | GCGCPB2OGA | |
| SCHEMBL22199018 | 0.78 | CYP2E1 (0.44) | CNR2NPC1IDH1SMN1; SMN2 | |
| SCHEMBL21668010 | 0.78 | MAP4K4 (0.42) | IDH1 | |
| SCHEMBL7172187 | 0.75 | CPB2 (0.35) | CPB2CNR2NPC1ALDH1A1P2RX3 | |
| SCHEMBL22185839 | 0.73 | CPB2 (0.44) | CPB2NPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22185260 | 0.73 | HTR3E (0.41) | NPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22185893 | 0.72 | SCD (0.36) | GCGOGA | |
| SCHEMBL22185891 | 0.72 | RPS6KA5 (0.33) | GCG | |
| SCHEMBL12841348 | 0.71 | CNR2 (0.40) | CNR2NPC1ALDH1A1GPR119MAPT | |
| SCHEMBL22185262 | 0.71 | POLB (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | PANK3 2102/4885GCG 1742/4885CPB2 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.